Identification of novel candidate oncogenes in chromosome region 17p11.2-p12 in human osteosarcoma

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Both, Joeri ^a   Wu, Thijs ^a   Bras, Johannes ^a   Schaap, Gerard R ^a   Baas, Frank ^a   Hulsebos, Theo J M ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CARCINOGENESIS; CHILD; CHROMOSOME 17P; FEMALE; GENE ACTIVATION; GENE AMPLIFICATION; GENE DOSAGE; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE IDENTIFICATION; GENE LOCATION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MARKER GENE; ONCOGENE; ONCOGENE ALKBH5; ONCOGENE C17ORF39; ONCOGENE C17ORF45; ONCOGENE COPS3; ONCOGENE GRAP; ONCOGENE PMP22; ONCOGENE PRPSAP2; ONCOGENE RASD1; ONCOGENE RICH2; ONCOGENE SHMT1; ONCOGENE TOP3A; OSTEOSARCOMA; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; QUANTITATIVE ANALYSIS; SCHOOL CHILD; SENSITIVITY ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; BONE TUMOR; CHROMOSOME 17; COHORT ANALYSIS; DNA MICROARRAY; GENETICS; METHODOLOGY; MIDDLE AGED; MOLECULAR CLONING; PATHOLOGY; TUMOR CELL CULTURE;

ADOLESCENT; ADULT; AGED; BONE NEOPLASMS; CHILD; CHROMOSOMES, HUMAN, PAIR 17; CLONING, MOLECULAR; COHORT STUDIES; FEMALE; GENETIC ASSOCIATION STUDIES; HUMANS; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ONCOGENES; OSTEOSARCOMA; TUMOR CELLS, CULTURED; YOUNG ADULT;

EID: 84856256081     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0030907     Document Type: Article

References (54)

1. Lietman SA, Joyce MJ, (2010) Bone sarcomas: Overview of management, with a focus on surgical treatment considerations. Cleve Clin J Med 77 (Suppl 1): S8-12.
2. Ottaviani G, Jaffe N, (2010) The epidemiology of osteosarcoma. Cancer Treat Res 152: 3-13.
3. Benayahu D, Shur I, Marom R, Meller I, Issakov J, (2001) Cellular and molecular properties associated with osteosarcoma cells. J Cell Biochem 84: 108-114.
4. Gordon N, Kleinerman ES, (2010) Aerosol therapy for the treatment of osteosarcoma lung metastases: targeting the Fas/FasL pathway and rationale for the use of gemcitabine. J Aerosol Med Pulm Drug Deliv 23: 189-196.
5. Bacci G, Bertoni F, Longhi A, Ferrari S, Forni C, et al. (2003) Neoadjuvant chemotherapy for high-grade central osteosarcoma of the extremity. Histologic response to preoperative chemotherapy correlates with histologic subtype of the tumor. Cancer 97: 3068-3075.
6. Hawkins DS, Arndt CA, (2003) Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapy. Cancer 98: 2447-2456.
7. Sandberg AA, Bridge JA, (2003) Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: osteosarcoma and related tumors. Cancer Genet Cytogenet 145: 1-30.
8. Forus A, Weghuis DO, Smeets D, Fodstad O, Myklebost O, et al. (1995) Comparative genomic hybridization analysis of human sarcomas: II. Identification of novel amplicons at 6p and 17p in osteosarcomas. Genes Chromosomes Cancer 14: 15-21.
9. Lau CC, Harris CP, Lu XY, Perlaky L, Gogineni S, et al. (2004) Frequent amplification and rearrangement of chromosomal bands 6p12-p21 and 17p11.2 in osteosarcoma. Genes Chromosomes Cancer 39: 11-21.
10. Selvarajah S, Yoshimoto M, Ludkovski O, Park PC, Bayani J, et al. (2008) Genomic signatures of chromosomal instability and osteosarcoma progression detected by high resolution array CGH and interphase FISH. Cytogenet Genome Res 122: 5-15.
11. Gamberi G, Benassi MS, Bohling T, Ragazzini P, Molendini L, et al. (1998) C-myc and c-fos in human osteosarcoma: prognostic value of mRNA and protein expression. Oncology 55: 556-563.
12. Lu XY, Lu Y, Zhao YJ, Jaeweon K, Kang J, et al. (2008) Cell cycle regulator gene CDC5L, a potential target for 6p12-p21 amplicon in osteosarcoma. Mol Cancer Res 6: 937-946.
13. Sadikovic B, Thorner P, Chilton-MacNeill S, Martin JW, Cervigne NK, et al. (2010) Expression analysis of genes associated with human osteosarcoma tumors shows correlation of RUNX2 overexpression with poor response to chemotherapy. BMC Cancer 10: 202.
14. van Dartel M, Redeker S, Bras J, Kool M, Hulsebos TJ, (2004) Overexpression through amplification of genes in chromosome region 17p11.2 approximately p12 in high-grade osteosarcoma. Cancer Genet Cytogenet 152: 8-14.
15. Atiye J, Wolf M, Kaur S, Monni O, Bohling T, et al. (2005) Gene amplifications in osteosarcoma-CGH microarray analysis. Genes Chromosomes Cancer 42: 158-163.
16. Kaur S, Larramendy ML, Vauhkonen H, Bohling T, Knuutila S, (2007) Loss of TP53 in sarcomas with 17p12 to approximately p11 gain. A fine-resolution oligonucleotide array comparative genomic hybridization study. Cytogenet Genome Res 116: 153-157.
17. Man TK, Lu XY, Jaeweon K, Perlaky L, Harris CP, et al. (2004) Genome-wide array comparative genomic hybridization analysis reveals distinct amplifications in osteosarcoma. BMC Cancer 4: 45.
18. Squire JA, Pei J, Marrano P, Beheshti B, Bayani J, et al. (2003) High-resolution mapping of amplifications and deletions in pediatric osteosarcoma by use of CGH analysis of cDNA microarrays. Genes Chromosomes Cancer 38: 215-225.
19. van Dartel M, Cornelissen PW, Redeker S, Tarkkanen M, Knuutila S, et al. (2002) Amplification of 17p11.2 approximately p12, including PMP22, TOP3A, and MAPK7, in high-grade osteosarcoma. Cancer Genet Cytogenet 139: 91-96.
20. Rui L, Emre NC, Kruhlak MJ, Chung HJ, Steidl C, et al. (2010) Cooperative epigenetic modulation by cancer amplicon genes. Cancer Cell 18: 590-605.
21. Yang ZQ, Streicher KL, Ray ME, Abrams J, Ethier SP, (2006) Multiple interacting oncogenes on the 8p11-p12 amplicon in human breast cancer. Cancer Res 66: 11632-11643.
22. Attiyeh EF, Diskin SJ, Attiyeh MA, Mosse YP, Hou C, et al. (2009) Genomic copy number determination in cancer cells from single nucleotide polymorphism microarrays based on quantitative genotyping corrected for aneuploidy. Genome Res 19: 276-283.
23. Hupe P, Stransky N, Thiery JP, Radvanyi F, Barillot E, (2004) Analysis of array CGH data: from signal ratio to gain and loss of DNA regions. Bioinformatics 20: 3413-3422.
24. Beroukhim R, Getz G, Nghiemphu L, Barretina J, Hsueh T, et al. (2007) Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A 104: 20007-20012.
25. Lockwood WW, Stack D, Morris T, Grehan D, O'Keane C, et al. (2011) Cyclin E1 is amplified and overexpressed in osteosarcoma. J Mol Diagn 13: 289-296.
26. Albertson DG, (2006) Gene amplification in cancer. Trends Genet 22: 447-455.
27. Schwab M, (2004) MYCN in neuronal tumours. Cancer Lett 204: 179-187.
28. Henriksen J, Aagesen TH, Maelandsmo GM, Lothe RA, Myklebost O, et al. (2003) Amplification and overexpression of COPS3 in osteosarcomas potentially target TP53 for proteasome-mediated degradation. Oncogene 22: 5358-5361.
29. Yan T, Wunder JS, Gokgoz N, Gill M, Eskandarian S, et al. (2007) COPS3 amplification and clinical outcome in osteosarcoma. Cancer 109: 1870-1876.
30. Yan T, Tang G, Ren T, Shen D, Sun K, et al. (2011) RNAi-mediated COPS3 gene silencing inhibits metastasis of osteogenic sarcoma cells. Cancer Gene Ther 18: 450-456.
31. Naef R, Suter U, (1998) Many facets of the peripheral myelin protein PMP22 in myelination and disease. Microsc Res Tech 41: 359-371.
32. van Dartel M, Hulsebos TJ, (2004) Characterization of PMP22 expression in osteosarcoma. Cancer Genet Cytogenet 152: 113-118.
33. Huhne K, Park O, Liehr T, Rautenstrauss B, (1999) Expression analysis of the PMP22 gene in glioma and osteogenic sarcoma cell lines. J Neurosci Res 58: 624-631.
34. Evtimova V, Zeillinger R, Weidle UH, (2003) Identification of genes associated with the invasive status of human mammary carcinoma cell lines by transcriptional profiling. Tumour Biol 24: 189-198.
35. Li J, Kleeff J, Esposito I, Kayed H, Felix K, et al. (2005) Expression analysis of PMP22/Gas3 in premalignant and malignant pancreatic lesions. J Histochem Cytochem 53: 885-893.
36. Rao RG, Sudhakar D, Hogue CP, Amici S, Gordon LK, et al. (2011) Peripheral myelin protein-22 (PMP22) modulates alpha 6 integrin expression in the human endometrium. Reprod Biol Endocrinol 9: 56.
37. Manfioletti G, Ruaro ME, Del SG, Philipson L, Schneider C, (1990) A growth arrest-specific (gas) gene codes for a membrane protein. Mol Cell Biol 10: 2924-2930.
38. Furuta B, Harada A, Kobayashi Y, Takeuchi K, Kobayashi T, et al. (2002) Identification and functional characterization of nadrin variants, a novel family of GTPase activating protein for rho GTPases. J Neurochem 82: 1018-1028.
39. Richnau N, Aspenstrom P, (2001) Rich, a rho GTPase-activating protein domain-containing protein involved in signaling by Cdc42 and Rac1. J Biol Chem 276: 35060-35070.
40. Akavia UD, Litvin O, Kim J, Sanchez-Garcia F, Kotliar D, et al. (2010) An integrated approach to uncover drivers of cancer. Cell 143: 1005-1017.
41. Vaidyanathan G, Cismowski MJ, Wang G, Vincent TS, Brown KD, et al. (2004) The Ras-related protein AGS1/RASD1 suppresses cell growth. Oncogene 23: 5858-5863.
42. Yasuda T, Kanamori M, Nogami S, Hori T, Oya T, et al. (2009) Establishment of a new human osteosarcoma cell line, UTOS-1: cytogenetic characterization by array comparative genomic hybridization. J Exp Clin Cancer Res 28: 26.
43. Jarvinen TA, Liu ET, (2003) Topoisomerase IIalpha gene (TOP2A) amplification and deletion in cancer-more common than anticipated. Cytopathology 14: 309-313.
44. Kanta SY, Yamane T, Dobashi Y, Mitsui F, Kono K, et al. (2006) Topoisomerase IIalpha gene amplification in gastric carcinomas: correlation with the HER2 gene. An immunohistochemical, immunoblotting, and multicolor fluorescence in situ hybridization study. Hum Pathol 37: 1333-1343.
45. Kobayashi K, Nishioka M, Kohno T, Nakamoto M, Maeshima A, et al. (2004) Identification of genes whose expression is upregulated in lung adenocarcinoma cells in comparison with type II alveolar cells and bronchiolar epithelial cells in vivo. Oncogene 23: 3089-3096.
46. Simon R, Atefy R, Wagner U, Forster T, Fijan A, et al. (2003) HER-2 and TOP2A coamplification in urinary bladder cancer. Int J Cancer 107: 764-772.
47. Guerin E, Entz-Werle N, Eyer D, Pencreac'h E, Schneider A, et al. (2003) Modification of topoisomerase genes copy number in newly diagnosed childhood acute lymphoblastic leukemia. Leukemia 17: 532-540.
48. Brase JC, Schmidt M, Fischbach T, Sultmann H, Bojar H, et al. (2010) ERBB2 and TOP2A in breast cancer: a comprehensive analysis of gene amplification, RNA levels, and protein expression and their influence on prognosis and prediction. Clin Cancer Res 16: 2391-2401.
49. Lightfoot TJ, Johnston WT, Painter D, Simpson J, Roman E, et al. (2010) Genetic variation in the folate metabolic pathway and risk of childhood leukemia. Blood 115: 3923-3929.
50. Vijayakrishnan J, Houlston RS, (2010) Candidate gene association studies and risk of childhood acute lymphoblastic leukemia: a systematic review and meta-analysis. Haematologica 95: 1405-1414.
51. Kelemen LE, Sellers TA, Schildkraut JM, Cunningham JM, Vierkant RA, et al. (2008) Genetic variation in the one-carbon transfer pathway and ovarian cancer risk. Cancer Res 68: 2498-2506.
52. Collin SM, Metcalfe C, Zuccolo L, Lewis SJ, Chen L, et al. (2009) Association of folate-pathway gene polymorphisms with the risk of prostate cancer: a population-based nested case-control study, systematic review, and meta-analysis. Cancer Epidemiol Biomarkers Prev 18: 2528-2539.
53. Pimkin M, Pimkina J, Markham GD, (2009) A regulatory role of the Bateman domain of IMP dehydrogenase in adenylate nucleotide biosynthesis. J Biol Chem 284: 7960-7969.
54. Fabris S, Todoerti K, Mosca L, Agnelli L, Intini D, et al. (2007) Molecular and transcriptional characterization of the novel 17p11.2-p12 amplicon in multiple myeloma. Genes Chromosomes Cancer 46: 1109-1118.